Bone Research review maps multiscale skeletal degeneration and rejuvenation strategies

A comprehensive review in Bone Research details bone aging as a multiscale network of molecular, cellular, and microenvironmental decline, providing a system-level blueprint for next-generation therapeutic rejuvenation.

On September 14, 2026, researchers at the Peking University Third Hospital and affiliated institutions published a comprehensive review in Bone Research synthesizing the multiscale degenerative cascade of bone aging.

At the macroscopic level, the publication outlines age-related bone mass loss, structural deterioration (including cortical porosification and trabecular fragmentation), and mechanical declines, noting that vertebral stress resistance can decrease by 75% to 80% while bone mineral density falls by only 48% to 50% between ages 20 and 80.

At the microscopic level, the pathogenesis involves genomic instability, epigenetic reprogramming, oxidative stress, and the tissue-specific senescence-associated secretory phenotype (SASP), alongside cell-level lesions in mitochondria, endoplasmic reticulum, and nutrient-sensing pathways (including insulin/IGF-1, mTORC1, AMPK, and sirtuins).

The therapeutic landscape surveyed includes established antiresorptives (bisphosphonates, denosumab, SERMs) and anabolic agents (teriparatide, abaloparatide, romosozumab), alongside emerging senolytics, sirtuin activators, stem cell therapies, and bone-targeted AAV gene therapies.

Traditional therapeutic approaches have predominantly focused on bone mass (BMD) alone, failing to address the underlying quality, microarchitecture, and biological drivers of skeletal fragility.

By establishing bone aging as a networked, multi-organ degenerative phenomenon, the review provides a scientific rationale for the clinical translation of geroscience-derived interventions like senolytics and epigenetic clocks.

The paper highlights key translational gaps, noting that conventional murine aging models fail to replicate the decades-long process of human bone accrual and remodeling, which historically hampers clinical success rates.

The review's emphasis on molecular mechanisms like Wnt signaling, sirtuin decline, and cellular senescence highlights the strategic alignment of biotech companies targeting these pathways to treat skeletal and joint diseases.

Clinical results cited—such as the Phase 2 trial of intermittent dasatinib and quercetin showing significant increases in the bone formation marker P1NP—provide commercial validation for companies developing targeted senolytics.

The highlight of high translational failure rates from murine models underscores a growing market opportunity for advanced in vitro models, such as 3D bone organoids and digital predictive systems, to accelerate drug development.

The development of multi-omics integrated bone aging atlases to map cell-to-cell communication networks at single-cell resolution.

Preclinical and clinical trial progression of bone-targeted AAV gene therapies delivering Wnt-modulating gene silencers.

Long-term efficacy and fracture-reduction data from human clinical trials utilizing senolytics or senomorphics to ameliorate the pro-inflammatory bone microenvironment.